CN1320913C - Medicine for treating toxuria - Google Patents
Medicine for treating toxuria Download PDFInfo
- Publication number
- CN1320913C CN1320913C CNB2005100499843A CN200510049984A CN1320913C CN 1320913 C CN1320913 C CN 1320913C CN B2005100499843 A CNB2005100499843 A CN B2005100499843A CN 200510049984 A CN200510049984 A CN 200510049984A CN 1320913 C CN1320913 C CN 1320913C
- Authority
- CN
- China
- Prior art keywords
- rhizoma
- portions
- parts
- medicine
- present
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The present invention discloses a medicine for treating toxuria, which is made from the traditional Chinese medicines of 2 to 5 portions of cassia bark, 7 to 13 portions of phellodendron bark, 7 to 13 portions of common anemarrhena rhizome, 4 to 8 portions of bamboo shavings, 4 to 8 portions of coptis, 4 to 8 portions of faxia, 8 to 15 portions of tuckahoe and 8 to 15 portions of water plantain according to the proportion by weight. Through the clinical verification, the present invention has the favorable efficiency of nourishing yin, clearing heat, transforming Qi, dredging water and controlling yin and yang; compared with the existing medicament, the present invention has the advantages of better therapeutic effect, no toxic or side effect and lower therapeutic expense when used for treating toxuria.
Description
Technical field:
The present invention relates to the uremic medicine of a kind of treatment, belong to the technical field of pharmaceuticals for the treatment of uraemia.
Background technology:
Uremia is a kind of common disease, is owing to renal failure, the group of toxic symptoms that the metabolite acatharsia is produced.Though it is more to treat the medicine of this disease at present, mostly is Western medicine greatly, though these Western medicine have certain curative effect, it exists the phenomenon of toxic and side effects also relatively more serious; It is higher that existing in addition Western medicine ubiquity medical expense, and the also less-than-ideal problem of curative effect, and therefore, the result of use of existing treatment uraemia medicine still is not ideal.
Summary of the invention:
The objective of the invention is: provide a kind of therapeutic effect better, have no side effect, the medicine of treatment uraemia that medical expense is lower, to overcome the deficiencies in the prior art.
The present invention is achieved in that the medicament that this medicine is made by Cortex Cinnamomi, Cortex Phellodendri, the Rhizoma Anemarrhenae, Caulis Bambusae In Taenia, Rhizoma Coptidis, Rhizoma Pinelliae Preparata, Poria and Rhizoma Alismatis eight flavor Chinese medicines, each Chinese medicine proportioning by weight of distinguishing the flavor of is: 2～5 parts of Cortex Cinnamomis, each 7～13 parts of the Cortex Phellodendri and the Rhizoma Anemarrhenaes, each 4～8 parts of Caulis Bambusae In Taenia, Rhizoma Coptidis and Rhizoma Pinelliae Preparata, each 8～15 parts of Poria and Rhizoma Alismatis.
The ratio range of the formula optimization weight portion of preparation medicine of the present invention is: 3～4 parts of Cortex Cinnamomis, each 9～11 parts of the Cortex Phellodendri and the Rhizoma Anemarrhenaes, each 5～7 parts of Caulis Bambusae In Taenia, Rhizoma Coptidis and Rhizoma Pinelliae Preparata, each 10～13 parts of Poria and Rhizoma Alismatis.
The proportioning of optimum weight part of medicine of the present invention is: 3 parts of Cortex Cinnamomis, each 10 parts of the Cortex Phellodendri and the Rhizoma Anemarrhenaes, each 6 parts of Caulis Bambusae In Taenia, Rhizoma Coptidis and Rhizoma Pinelliae Preparata, each 12 parts of Poria and Rhizoma Alismatis.
The said medicament of the present invention is a said dosage form on any pharmaceutics.
Best medicament of the present invention is an oral liquid formulation.
In prescription of the present invention: the Cortex Cinnamomi extremely hot in nature, hide hot, sweet, have mend that fire is supporing yang, the effect of let the fire back to its origin, dispersing cold for relieving pain, promoting blood circulation to restore menstrual flow; Cortex Phellodendri property hardship, cold is returned kidney, urinary bladder channel, has heat clearing and damp drying, pathogenic fire purging except that the effect of steaming, skin ulcer is treated in detoxifcation; Rhizoma Anemarrhenae hardship, sweet, cold is returned lung, stomach, kidney channel, has clearing away heat-fire, nourshing Yin and drynsessmoistening prescription effect; Caulis Bambusae In Taenia is sweet, be slightly cold, and attaches to the lung and stomach meridians the effect that have removing heat-phlegm, relieves restlessness and prevents vomiting; Cold in nature, the bitter in the mouth of Rhizoma Coptidis has heat clearing and damp drying, the effect of removing water retention by purgation detoxifcation; Rhizoma Pinelliae Preparata has the effect of regulating the stomach and sending down the abnormal ascending QI; That Poria is hidden is sweet, light, property flat, has the effect of promoting diuresis to eliminate damp pathogen, spleen invigorating mind calming; Rhizoma Alismatis property is sweet, and is cold, returns kidney, urinary bladder channel, has the effect of diuresis, clearing away damp-heat.
The present invention is according to traditional experience, and in conjunction with the pathomechanism of modern medicine, think that uremia and liver,spleen,kidney have substantial connection, because of the kidney being the origin of congenital constitution, main water, store essential substances, the essence of five ZANG-organs and six FU-organs system is hidden in kidney, deficiency of kidney-QI, dysfunction of the kidney in storing essence, vital essence leak and then phenomenons such as albumen, leukocyte, cast occur in the urine; And the spleen being the foundation of acquired constitution has the merit of cloudization, the usefulness of controlling the water circulation; Stomach is a reservoir of food and drink, and main Na Shuigu is the source of vital function, and the Semen arachidis hypogaeae of QI and blood is played an important role.Therefore the function of kidney, spleen, stomach is with uremic generation and lapsed to confidential relation.It is considered herein that uremia is exactly that kidney yang is weak, Kidney-Yin loss, make the hypofunction of kidney own, simultaneously again because of deficiency of spleen-QI loses, transporting and transforming nutrients from foodstuff is precise and tiny unable, the biochemical resource shortage of QI and blood, form the QI and blood loss, the blood supply of kidney own lacks, and causes renal function to fail day by day, undermine essence, disturbance in functioning of QI and urine retention.So often show as asthenia of both the spleen and kidney late stage of uremia.Therefore the present invention is directed to uremic characteristics, through long-term experiment, comparison and research, above-mentioned inexpensive and Chinese medicine that have no side effect commonly used carried out rational formula after, make the Chinese medicine of respectively distinguishing the flavor of can coordinate to bring into play jointly it mutually to transfer property of medicine of spleen reinforcing kidney.Through clinical verification, the present invention has the effect of nourishing YIN and clearing away heat, promote the circulation of qi and water, Yang-deficiency governing preferably, and when being used for the treatment of uraemia, compare with existing medicine, the present invention also have therapeutic effect better, have no side effect, advantage that medical expense is lower.
The specific embodiment:
Embodiments of the invention: get Cortex Cinnamomi 3 grams, each 10 gram of the Cortex Phellodendri and the Rhizoma Anemarrhenae, each 6 gram of Caulis Bambusae In Taenia, Rhizoma Coptidis and Rhizoma Pinelliae Preparata, each 12 gram of Poria and Rhizoma Alismatis are as pharmaceutical raw material, each raw material is cleaned the back to be soaked 20～30 minutes earlier with 800～1000 ml waters, decocted again 20～50 minutes after then it being boiled, medicinal residues are filtered out, get its medicinal liquid and can make oral liquid formulations of the present invention.Oral liquid formulations of the present invention also routinely the oral liquid processing technology be made; And other dosage form (as dosage forms such as tablet, pill, capsules) can be made by the method for corresponding conventional dosage form.
The instructions about how to take medicine of oral liquid formulations of the present invention are: every day 3 times, each 30～50 milliliters, general 2 weeks to 1 month are a course of treatment.
Be the clinical observation that employing the present invention treats uremic patient below, so that curative effect of the present invention is further described:
Medical history patient exaggerates because of work, causes lumbago, edema, and does not draw attention, and continues to do manual work, and occurs frequent micturition, urgent micturition afterwards, and develops into urine retention gradually, and vomiting and nausea can not be taken food, anasarca, 38 ℃～40 ℃ of hyperpyrexia.Through examination in hospital, be diagnosed as " chronic nephritis, uremia " and be in hospital.Through using western medicine, the symptom commentaries on classics of not getting better.The back adopts the present invention to treat.Chemically examining the CO2 combining power, CO2 CP of finding the patient on inspection before the treatment is 41.3 volume %, 96 milligrams of % of non-protein nitrogen, urine protein (+++).
The patient took the present invention after 5 days, and vomiting reduces, urine is drained more normally, and every day, the urine amount reached 2500 milliliters, and color is yellowish, and through the routine that has urine examined: proportion 1.012, urine protein (++) is not seen cast.Continue to take the present invention.
The patient is taking the present invention after 25 days, and through laboratory examination, its CO2 combining power, CO2 CP is 30.1 volume %, 56.2 milligrams of % of non-protein nitrogen, urine protein (+).The patient continues to take the present invention after 5 days again, its symptom complete obiteration, and muscle power is recovered substantially, and routine urianlysis is normal.
Taking during the present invention treats, any untoward reaction does not appear in the patient.
Claims (3)
1, the uremic medicine of a kind of treatment, it is characterized in that: the medicament that this medicine is made by Cortex Cinnamomi, Cortex Phellodendri, the Rhizoma Anemarrhenae, Caulis Bambusae In Taenia, Rhizoma Coptidis, Rhizoma Pinelliae Preparata, Poria and Rhizoma Alismatis eight flavor Chinese medicines, each Chinese medicine proportioning by weight of distinguishing the flavor of is: 2～5 parts of Cortex Cinnamomis, each 7～13 parts of the Cortex Phellodendri and the Rhizoma Anemarrhenaes, each 4～8 parts of Caulis Bambusae In Taenia, Rhizoma Coptidis and Rhizoma Pinelliae Preparata, each 8～15 parts of Poria and Rhizoma Alismatis.
2, the uremic medicine of treatment according to claim 1 is characterized in that: each Chinese medicine proportioning by weight of distinguishing the flavor of is: 2～4 parts of Cortex Cinnamomis, each 9～11 parts of the Cortex Phellodendri and the Rhizoma Anemarrhenaes, each 5～7 parts of Caulis Bambusae In Taenia, Rhizoma Coptidis and Rhizoma Pinelliae Preparata, each 10～13 parts of Poria and Rhizoma Alismatis.
3, the uremic medicine of treatment according to claim 1 is characterized in that: each Chinese medicine proportioning by weight of distinguishing the flavor of is: 3 parts of Cortex Cinnamomis, each 10 parts of the Cortex Phellodendri and the Rhizoma Anemarrhenaes, each 6 parts of Caulis Bambusae In Taenia, Rhizoma Coptidis and Rhizoma Pinelliae Preparata, each 12 parts of Poria and Rhizoma Alismatis.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005100499843A CN1320913C (en) | 2005-06-07 | 2005-06-07 | Medicine for treating toxuria |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005100499843A CN1320913C (en) | 2005-06-07 | 2005-06-07 | Medicine for treating toxuria |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1709492A CN1709492A (en) | 2005-12-21 |
| CN1320913C true CN1320913C (en) | 2007-06-13 |
Family
ID=35705823
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2005100499843A Expired - Fee Related CN1320913C (en) | 2005-06-07 | 2005-06-07 | Medicine for treating toxuria |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1320913C (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1446571A (en) * | 2003-04-14 | 2003-10-08 | 曾力群 | Pure Chinese herbal medicine formulation for treating nephritis |
-
2005
- 2005-06-07 CN CNB2005100499843A patent/CN1320913C/en not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1446571A (en) * | 2003-04-14 | 2003-10-08 | 曾力群 | Pure Chinese herbal medicine formulation for treating nephritis |
Non-Patent Citations (4)
| Title |
|---|
| 中西医结合治疗急笥肾功能衰竭32例总结 郑水源，湖南中医杂志，第17卷第6期 2001 * |
| 帅焘主任治疗慢性肾功能衰竭的经验 龙渊等，云南中医中药杂志，第23卷第3期 2002 * |
| 慢性肾炎转变为尿毒症的临床治疗探讨 赵毓，新中医，第29卷第S1期 1997 * |
| 慢性肾炎转变为尿毒症的临床治疗探讨 赵毓，新中医，第29卷第S1期 1997;帅焘主任治疗慢性肾功能衰竭的经验 龙渊等，云南中医中药杂志，第23卷第3期 2002;中西医结合治疗急笥肾功能衰竭32例总结 郑水源，湖南中医杂志，第17卷第6期 2001 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1709492A (en) | 2005-12-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103690742A (en) | Traditional Chinese medicine composition for anti-diarrhea and anti-dysentery | |
| CN104027517A (en) | Traditional Chinese medicine for treating acute enteritis | |
| CN102423444B (en) | Traditional Chinese medicine preparation for treating rheumatism and internal lesion caused by overexertion and preparation method thereof | |
| CN104547633B (en) | A kind of Chinese medicine composition for treating cervical spondylopathy and preparation method thereof | |
| CN101167907A (en) | Compound preparation for treating hyperosteogeny and preparation process thereof | |
| CN103356925B (en) | Traditional Chinese medicine composition for treating sperm non-liquified symptom | |
| CN105999057A (en) | Traditional Chinese medicine for treating diabetics | |
| CN102895610A (en) | Medicine for treating edema | |
| CN102641471B (en) | Traditional Chinese medicine for treating cholelithiasis | |
| CN1320913C (en) | Medicine for treating toxuria | |
| CN104758726A (en) | Traditional Chinese medicine composition for treating urinary tract infection | |
| CN105106895B (en) | A kind of herbal mixture oral solution that treating ephritis and its preparation process | |
| CN103405743A (en) | Drug preparation for infantile diarrhea | |
| CN1320899C (en) | Medicine for treating ulcer haemorrhage | |
| CN106236857B (en) | Traditional Chinese medicine composition for treating chronic renal failure and preparation method, preparation and application thereof | |
| CN104971302A (en) | Traditional Chinese medicine composition for treating biliary tract ascariasis | |
| CN103638232B (en) | One treats rheumatismal Chinese medicine composition | |
| CN116350731B (en) | Formula for clearing heat, removing dampness and relieving arthralgia as well as preparation and application thereof | |
| CN102973839A (en) | Chinese patent medicine granules for treating chronic gastritis | |
| CN103877374B (en) | A kind of for Chinese medicine treating diabetes and preparation method thereof | |
| CN105878198A (en) | Pharmaceutical composition containing berberine hydrochloride tablets and preparation process thereof | |
| CN104784596A (en) | Traditional Chinese medicine for treating ankylosing spondylitis | |
| CN101085316A (en) | Traditional Chinese medicine preparation for treating menstrual vertigo | |
| CN104043047A (en) | Traditional Chinese medicine for treating chronic pancreatitis | |
| CN104001044A (en) | Traditional Chinese medicine composition treating hyperlipidemia |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20070613 |